Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Provectus Pharmaceuticals, Inc. (PVCT-OCT: BB) |
|
|
We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D. (PVCT) (Interview published April 12, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Provectus News Maxim Group Issues
Company Update on Provectus Following the announcement yesterday of the completion of the first end-of-Phase II meeting with the FDA for discussion of the future clinical path of PV-10 for melanoma, Maxim Group, LLC has issued a Company Update on Provectus. A copy of the update in PDF format is attached. If you cannot read the attached copy, or would like to request a copy, please contact Marlon Nurse of Porter, LeVay, & Rose at +1 (212)-564-4700, or e-mail Peter Culpepper, CFO/COO at culpepper@pvct.com.
|
|
